Estradiol / Norethindrone
Estradiol / norethindrone is a combination estrogen and progestin hormone therapy used to treat moderate to severe menopausal symptoms and to help prevent postmenopausal osteoporosis.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 12 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
This medicine carries a serious FDA boxed warning about cancer, heart problems, and dementia. Taking estrogen plus progestin has been linked to a higher risk of heart attack, stroke, blood clots (deep vein thrombosis and pulmonary embolism), and invasive breast cancer. Studies in women 65 and older also found a higher risk of probable dementia. Do not use this medicine to prevent heart disease, stroke, or dementia — it is not approved for those purposes and may actually increase those risks. Using estrogen alone (without a progestin) in women who still have a uterus raises the risk of uterine (endometrial) cancer. The risks of estrogen plus progestin therapy were studied primarily with one specific product and dose; how much these risks apply to other products and doses, including this one, is not fully known. Talk with your doctor regularly about whether the benefits still outweigh the risks for you personally.
📖 Estradiol / Norethindrone: Patient Information Guide
A plain-language walkthrough of Estradiol / Norethindrone — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Estradiol / norethindrone is a combination hormone therapy approved for postmenopausal women who still have a uterus. Here is the full set of supported uses across available products:
- Moderate to severe vasomotor symptoms (hot flashes, night sweats) due to menopause — supported by all oral tablet products and CombiPatch
- Moderate to severe vulvar and vaginal atrophy symptoms (dryness, irritation, painful intercourse) due to menopause — supported by all oral tablet products and CombiPatch; topical vaginal products should be considered first if this is the only reason for treatment
- Prevention of postmenopausal osteoporosis (bone thinning after menopause) — supported by oral tablet products; non-estrogen medications should be considered first if osteoporosis prevention is the sole reason for use, and estrogen should be reserved for women at significant risk
- CombiPatch (the transdermal patch) is additionally approved for treatment of low estrogen due to hypogonadism (underactive ovaries), castration, or primary ovarian failure
⚙️How it works▾
After menopause, estrogen levels drop sharply. Estradiol is the main active estrogen in the body — it binds to estrogen receptors in tissues like the brain, vagina, and bone, helping to ease hot flashes, reverse vaginal changes, and slow the bone loss that follows menopause. Norethindrone acetate is a progestin (a synthetic progesterone-like hormone) that balances estrogen's effects on the uterine lining, reducing the risk of abnormal tissue growth (endometrial hyperplasia) that can develop when estrogen is used alone.
The progestin component works by binding to progesterone receptors, which counteract estrogen's stimulating effect on the uterus and help reduce estrogen receptor activity in target tissues.
💊How it's taken▾
Oral tablets are taken once daily by mouth. Taking the tablet with food does not meaningfully affect how estradiol is absorbed, though it may slightly alter the absorption profile of norethindrone. CombiPatch (the transdermal patch) is applied to the skin twice weekly on a rotating site. All forms should be used at the lowest dose that controls your symptoms, for the shortest time that meets your goals — your doctor should reassess this at regular visits.
- Oral tablets: once daily, with or without food
- CombiPatch: applied to skin, changed twice weekly, rotating sites
- Never adjust your dose on your own — always follow your prescriber's instructions
🤒Side effects — in detail▾
The most commonly reported side effects with oral estradiol / norethindrone acetate tablets include:
- Breast pain or tenderness
- Headache
- Nausea
- Back pain
- Vaginal bleeding or spotting after menopause
- Upper respiratory tract infections
- Insomnia
- Weight gain
- Sinus congestion (sinusitis)
- Emotional changes or mood swings
More serious reactions — including blood clots, stroke, heart attack, allergic reactions, and vision changes — require immediate medical attention. Stop the medicine and call your doctor or 911 right away if any of these occur.
⚠️Warnings & precautions▾
- Blood clots, stroke, and heart attack: Estrogen plus progestin therapy raises the risk of DVT (deep vein thrombosis), PE (pulmonary embolism), stroke, and heart attack. Stop this medicine immediately and seek emergency care if you develop sudden leg pain or swelling, chest pain, shortness of breath, or signs of stroke. Estrogen should be stopped at least 4 to 6 weeks before major surgery or extended bed rest.
- Breast cancer: Combined estrogen plus progestin therapy has been linked to an increased risk of invasive breast cancer. Get yearly breast exams and mammograms as recommended. Report any new breast lumps to your doctor.
- Uterine (endometrial) cancer: Using estrogen without a progestin in women who have a uterus increases endometrial cancer risk. The norethindrone in this combination helps reduce — but does not eliminate — that risk. Report any unexpected vaginal bleeding to your doctor promptly.
- Ovarian cancer: Hormone therapy has been associated with a modestly increased risk of ovarian cancer based on study data.
- Dementia: In women 65 and older, combined hormone therapy was linked to a higher risk of probable dementia. This medicine should not be used to prevent dementia.
- Gallbladder disease: Estrogen therapy raises the risk of gallbladder disease requiring surgery by 2 to 4 times.
- Liver disease: Do not use if you have active liver disease. Stop the medicine if cholestatic jaundice (yellowing of the skin due to bile flow problems) occurs.
- Vision changes: Retinal vascular thrombosis (a blood clot in the eye) has been reported. Stop the medicine and get an eye exam immediately if you have sudden vision loss or eye pain.
🔀What it interacts with▾
Several medicines and supplements can raise or lower hormone levels when taken with estradiol / norethindrone:
- St. John's wort (herbal supplement) — speeds up hormone breakdown, which can lower hormone levels and reduce effectiveness or cause irregular bleeding
- Seizure medicines (phenobarbital, carbamazepine) and rifampin (antibiotic) — also speed up breakdown of estradiol and norethindrone, potentially reducing their effect
- Antifungal medicines (ketoconazole, itraconazole) and antibiotics (erythromycin, clarithromycin) — slow hormone breakdown, which can raise levels and increase side effects
- Ritonavir (HIV medicine) — may increase hormone levels in the blood
- Grapefruit juice — may raise estradiol levels by slowing its breakdown in the gut and liver
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Do not use if you have unexplained or undiagnosed vaginal bleeding
- Do not use if you have or have had breast cancer, or other estrogen-dependent cancers
- Do not use if you have active blood clots (DVT or PE) or a history of them
- Do not use if you have had a stroke or heart attack, or have active arterial blood clot disease
- Do not use if you have active liver disease or liver impairment
- Do not use if you have an inherited clotting disorder (protein C, protein S, or antithrombin deficiency, or other thrombophilic conditions)
- Do not use if you have had a severe allergic reaction (anaphylaxis or angioedema) to this medicine
- Women 65 and older face higher risks of stroke, breast cancer, and probable dementia — discuss carefully with your doctor
- Not for use during pregnancy or in children
- Tell your doctor if you are breastfeeding — this medicine passes into breast milk and may reduce milk supply
- Tell your doctor if you take thyroid replacement hormone — estrogen can affect thyroid function tests and may require dose adjustments of thyroid medicine
🚑If you take too much▾
Taking too much of this medicine may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness, fatigue, and possibly unexpected vaginal bleeding. If an overdose is suspected, stop taking the medicine and contact a healthcare provider or poison control center for guidance on appropriate care.
📡Pharmacodynamics — effects in the body▾
Blood levels of estradiol do not reliably predict how well the medicine will work for an individual woman or what her risk of side effects will be. This means that measuring hormone levels in the blood cannot be used to compare how different estrogen products will perform in a given person, or to predict safety outcomes. Response to treatment varies from woman to woman regardless of measured concentrations.
🔬Pharmacokinetics — how your body processes it▾
After swallowing an oral tablet, estradiol is absorbed through the gastrointestinal tract and reaches peak blood levels within about 5 to 8 hours; norethindrone acetate is quickly converted to norethindrone and peaks within about 30 to 90 minutes. With daily dosing, steady-state blood levels are reached within about two weeks. Both hormones are mostly bound to proteins in the blood (albumin and SHBG) and are broken down primarily in the liver. Estradiol is metabolized into estrone and estriol, which are less active, and both estradiol and norethindrone are eventually excreted in urine and bile. Food does not significantly change how much estradiol is absorbed from the tablet, but it does modestly alter the absorption profile of norethindrone.
📦How to store it▾
Store in a dry place protected from light. Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° to 30°C (59° to 86°F) .
📄 Written from Estradiol / Norethindrone’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Estradiol / Norethindrone — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly is this medicine doing for me — why do I need both an estrogen and a progestin? ▾
What are the most important side effects I should actually watch out for? ▾
I've heard hormone therapy can cause cancer. How worried should I be? ▾
Are there any supplements or medications I should avoid while taking this? ▾
How long will I need to take this, and will I know when to stop? ▾
Is it safe to take this if I'm over 65? ▾
Is Estradiol / Norethindrone available over the counter? ▾
When was Estradiol / Norethindrone first available? ▾
Who makes Estradiol / Norethindrone? ▾
💬 Answers drafted from Estradiol / Norethindrone’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Estradiol / Norethindrone comes
Estradiol / Norethindrone is available in 3 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Tablet
How this form is used
- Treats moderate to severe hot flashes and night sweats (vasomotor symptoms) due to menopause
- Treats moderate to severe vaginal dryness and irritation (vulvar and vaginal atrophy) due to menopause
- Helps prevent postmenopausal osteoporosis (bone loss after menopause)
- Indicated for women who still have a uterus — the progestin component helps protect the uterine lining
- Abigale, Abigale Lo, Activella, and other oral tablets are taken once daily by mouth
- Tablets may be taken with or without food; taking with food may slightly reduce the peak level of norethindrone but does not meaningfully change overall absorption of estradiol
- Use the lowest effective dose for the shortest duration consistent with your treatment goals — discuss regularly with your doctor
- Do not stop or adjust your dose without talking to your prescriber first
Skin patch
How this form is used
- CombiPatch treats moderate to severe vasomotor symptoms (hot flashes, night sweats) due to menopause
- CombiPatch treats moderate to severe symptoms of vulvar and vaginal atrophy due to menopause
- CombiPatch is indicated for low estrogen levels caused by hypogonadism (underactive ovaries), castration, or primary ovarian failure
- CombiPatch is indicated for women with a uterus; when used only for vaginal symptoms, topical vaginal products should be considered first
- CombiPatch is applied to the skin (transdermal) and worn continuously; apply twice weekly
- CombiPatch should be started at the lowest dose; your prescriber will determine the appropriate regimen
- Rotate the application site with each new patch to avoid skin irritation
- CombiPatch should be used at the lowest effective dose for the shortest duration — your doctor should reassess your need for treatment periodically
Capsule
📊 Estradiol / Norethindrone across the U.S. market
How Estradiol / Norethindrone appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Estradiol / Norethindrone is used
A general measure of how commonly Estradiol / Norethindrone is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Estradiol / Norethindrone is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Estradiol / Norethindrone prescribed? Of the 1,596 medications we measure, Estradiol / Norethindrone ranks #675 by Medicaid prescriptions — more than 58% of them.
Utilization by Estradiol / Norethindrone product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
84 HR estradiol 0.00208 MG/HR / norethindrone acetate 0.00583 MG/HR Transdermal System Most dispensed
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1251493
84 HR estradiol 0.00208 MG/HR / norethindrone acetate 0.0104 MG/HR Transdermal System
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1251499
Other Estradiol / Norethindrone products — combination packs and listings not yet matched to a specific clinical product (kept visible so every prescription is accounted for)
Summed across the 11 of 34 listed NDC products with Medicaid activity.
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Estradiol / Norethindrone, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 13 of 38 listed Estradiol / Norethindrone NDCs with Medicaid activity.
🔍 Compare Estradiol / Norethindrone products
A representative set of FDA-listed product records for Estradiol / Norethindrone — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Capsule | ||||
| ETHINYL ESTRADIOL 20 mcg/1; NORETHINDRONE ACETATE 1 mg | — | Catalent Pharma Solutions, LLC | DRUG FOR FURTHER PROCESSING | View NDC → |
| 💊Skin patch | ||||
| ESTRADIOL 0.05 mg/d; NORETHINDRONE ACETATE 0.14 mg/d | Transdermal | Noven Therapeutics, LLC | NDA | View NDC → |
| ESTRADIOL 0.05 mg/d; NORETHINDRONE ACETATE 0.25 mg/d | Transdermal | Noven Therapeutics, LLC | NDA | View NDC → |
| 0.05; 0.14 mg/d; mg/d | Transdermal | Noven Therapeutics, LLC × 2 listings | NDA | View NDC → |
| 0.05; 0.25 mg/d; mg/d | Transdermal | Noven Therapeutics, LLC × 2 listings | NDA | View NDC → |
| 💊Tablet | ||||
| ESTRADIOL 0.5 mg/1; NORETHINDRONE ACETATE 0.1 mg | Oral | A-S Medication Solutions | ANDA | View NDC → |
| ESTRADIOL 1 mg/1; NORETHINDRONE ACETATE 0.5 mg | Oral | A-S Medication Solutions | ANDA | View NDC → |
| ESTRADIOL 0.5 mg/1; NORETHINDRONE ACETATE 0.1 mg | Oral | Amneal Pharmaceuticals LLC | NDA | View NDC → |
| ESTRADIOL 1 mg/1; NORETHINDRONE ACETATE 0.5 mg | Oral | Amneal Pharmaceuticals LLC | NDA | View NDC → |
| 0.5; 0.1 mg/1; mg | Oral | Amneal Pharmaceuticals LLC | NDA | View NDC → |
| 1; 0.5 mg/1; mg | Oral | Amneal Pharmaceuticals LLC | NDA | View NDC → |
| ESTRADIOL 0.5 mg/1; NORETHINDRONE ACETATE 0.1 mg | Oral | Amneal Pharmaceuticals NY LLC | NDA | View NDC → |
| ESTRADIOL 0.5 mg/1; NORETHINDRONE ACETATE 0.1 mg | Oral | Amneal Pharmaceuticals NY LLC | NDA AUTHORIZED GENERIC | View NDC → |
| ESTRADIOL 1 mg/1; NORETHINDRONE ACETATE 0.5 mg | Oral | Amneal Pharmaceuticals NY LLC | NDA AUTHORIZED GENERIC | View NDC → |
| ESTRADIOL 1 mg/1; NORETHINDRONE ACETATE 0.5 mg | Oral | Amneal Pharmaceuticals NY LLC | NDA | View NDC → |
| 0.5; 0.1 mg/1; mg | Oral | Amneal Pharmaceuticals NY LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 1; 0.5 mg/1; mg | Oral | Amneal Pharmaceuticals NY LLC × 2 listings | NDA | View NDC → |
| 1; 0.5 mg/1; mg | Oral | Amneal Pharmaceuticals NY LLC | NDA AUTHORIZED GENERIC | View NDC → |
| ESTRADIOL 0.5 mg/1; NORETHINDRONE ACETATE 0.1 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| ESTRADIOL 1 mg/1; NORETHINDRONE ACETATE 0.5 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 0.5; 0.1 mg/1; mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 1; 0.5 mg/1; mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| ESTRADIOL 0.5 mg/1; NORETHINDRONE ACETATE 0.1 mg | Oral | Breckenridge Pharmaceutical, Inc. | ANDA | View NDC → |
| ESTRADIOL 1 mg/1; NORETHINDRONE ACETATE 0.5 mg | Oral | Breckenridge Pharmaceutical, Inc. | ANDA | View NDC → |
| 0.5; 0.1 mg/1; mg | Oral | Breckenridge Pharmaceutical, Inc. | ANDA | View NDC → |
| 1; 0.5 mg/1; mg | Oral | Breckenridge Pharmaceutical, Inc. | ANDA | View NDC → |
| ESTRADIOL 0.5 mg/1; NORETHINDRONE ACETATE 0.1 mg | Oral | Ingenus Pharmaceuticals, LLC | ANDA | View NDC → |
| ESTRADIOL 1 mg/1; NORETHINDRONE ACETATE 0.5 mg | Oral | Ingenus Pharmaceuticals, LLC | ANDA | View NDC → |
| 0.5; 0.1 mg/1; mg | Oral | Ingenus Pharmaceuticals, LLC | ANDA | View NDC → |
| 1; 0.5 mg/1; mg | Oral | Ingenus Pharmaceuticals, LLC | ANDA | View NDC → |
| 0.5; 0.1 mg/1; mg | Oral | Lupin Pharmaceuticals, Inc. × 2 listings | ANDA | View NDC → |
| 1; 0.5 mg/1; mg | Oral | Lupin Pharmaceuticals, Inc. | ANDA | View NDC → |
| 0.5; 0.1 mg/1; mg | Oral | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| 1; 0.5 mg/1; mg | Oral | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| NORETHINDRONE ACETATE 0.5 mg/1; ESTRADIOL 1 mg | Oral | Naari Pte. Limited | ANDA | View NDC → |
| ESTRADIOL 1 mg/1; NORETHINDRONE ACETATE 0.5 mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| 1; 0.5 mg/1; mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| ESTRADIOL 0.5 mg/1; NORETHINDRONE ACETATE 0.1 mg | Oral | Xiromed LLC | ANDA | View NDC → |
| ESTRADIOL 1 mg/1; NORETHINDRONE ACETATE 0.5 mg | Oral | Xiromed LLC | ANDA | View NDC → |
Showing 43 of 43 products — FDA National Drug Code Directory. For the full list, search the NDC directory →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Estradiol / Norethindrone — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Estradiol / Norethindrone in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Estradiol / Norethindrone went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one exact multiple-ingredient concept (MIN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). A product with a different ingredient combination belongs on a different page.
RxCUI 214551 2 dose forms · 7 strengths
-
Dose form (SCDF) Oral Tablet RxCUI 372073In current FDA listingsClinical drug / strength (SCD) estradiol 0.5 MG / norethindrone acetate 0.1 MGRxCUI 1359123estradiol 1 MG / norethindrone acetate 0.5 MGRxCUI 1359126estradiol 2 MG / norethindrone 0.7 MGRxCUI 250838estradiol 2 MG / norethindrone 1 MGRxCUI 249869 -
Dose form (SCDF) Transdermal System RxCUI 1806052In current FDA listingsClinical drug / strength (SCD) 84 HR estradiol 0.00208 MG/HR / norethindrone acetate 0.00583 MG/HRRxCUI 125149384 HR estradiol 0.00208 MG/HR / norethindrone acetate 0.00708 MG/HRRxCUI 135929184 HR estradiol 0.00208 MG/HR / norethindrone acetate 0.0104 MG/HRRxCUI 1251499
Look up RxCUI 214551 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Estradiol / Norethindrone is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Estradiol / Norethindrone belongs to the Radioactive Diagnostic Agent class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 12 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Amneal Pharmaceuticals LLC is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.